Category: NeurometrixSyndicate content

NeuroMetrix tries Indiegogo for Quell OTC chronic pain device

March 5, 2015 by Mark Hollmer

Crowdfunding site Indiegogo is an unconventional marketing tool for the medical device world, but for NeuroMetrix it appears to have paid off.

NeuroMetrix tries Indiegogo for Quel OTC chronic pain device

Year in review: CEOs chime in on 2014

December 23, 2014 by MassDevice staff

MassDevice.com asks medical device CEOs about the key issues of 2014 and what's ahead for the New Year.

Year in review: CEOs chime in on 2014

As 2014 draws to a close, MassDevice.com asked several medical device company CEOs for their takes on 2014 and what they're looking for in 2015.

We wanted to get their views on the major trends seen in medtech this year, including the red-hot M&A and IPO scenes, the medical device tax, the regulatory environment in the U.S., and more.

NeuroMetrix names new consumer GM | Personnel Moves

September 4, 2014 by Brad Perriello

NeuroMetrix taps a Philips Oral Healthcare and Johnson & Johnson veteran to develop a consumer business for its over-the-counter pain management system.

NeuroMetrix names new consumer GM | Personnel Moves

NeuroMetrix wins FDA nod for over-the-counter chronic pain device

July 8, 2014 by Brad Perriello

NeuroMetrix says the FDA granted 510(k) clearance for over-the-counter sales of its wearable chronic pain device.

NeuroMetrix wins FDA nod for over-the-counter chronic pain device

Volcano's commercial sales prez bows out | Personnel Moves

July 1, 2014 by Brad Perriello

Jorge Quinoy, president of Volcano Corp.'s U.S. & APLAC commercial sales, is leaving the company effective today.

YYmeta

Volcano (NSDQ:VOLC) said last week that its president for U.S. & APLAC commercial sales, Jorge (George) Quinoy, is leaving the company effective today.

NeuroMetrix soars on Japanese market approval of diabetes test

June 24, 2014 by Arezu Sarvestani

NeuroMetrix's shares jump nearly 20% after the company lands Japanese marketing approval for its NC-stat DPNCheck for detecting diabetic peripheral neuropathy.

NeuroMetrix soars on Japanese market approval of diabetes test

NeuroMetrix (NSDQ:NURO) got a major Wall Street boost today after announcing Japanese market approval for its NC-stat DPNCheck test for diabetic peripheral neuropathy.